SEC Form 4 · accession 0001209191-16-091731
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jan 13, 2016
Accepted (ET)
Jan 15, 2016 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 13, 2016 | M | 10,400 | $35.64 | A | 275,684 | D | |
| Common StockF2,F3 | Jan 13, 2016 | S | 2,800 | $96.56 | D | 272,884 | D | |
| Common StockF2,F4 | Jan 13, 2016 | S | 2,300 | $97.25 | D | 270,584 | D | |
| Common StockF2,F5 | Jan 13, 2016 | S | 2,300 | $98.40 | D | 268,284 | D | |
| Common StockF2,F6 | Jan 13, 2016 | S | 600 | $99.84 | D | 267,684 | D | |
| Common StockF2,F7 | Jan 13, 2016 | S | 1,600 | $100.68 | D | 266,084 | D | |
| Common StockF2,F8 | Jan 13, 2016 | S | 400 | $102.37 | D | 265,684 | D | |
| Common StockF2,F9 | Jan 13, 2016 | S | 400 | $103.00 | D | 265,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401k | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F10 | $35.64 | Jan 13, 2016 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 21,600 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F10Fully vested.
- F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $96.56 (range $95.94 to $96.93).
- F4Open market sales reported on this line occurred at a weighted average price of $97.25 (range $96.95 to $97.81).
- F5Open market sales reported on this line occurred at a weighted average price of $98.40 (range $98.05 to $98.86).
- F6Open market sales reported on this line occurred at a weighted average price of $99.84 (range $99.22 to $100.18).
- F7Open market sales reported on this line occurred at a weighted average price of $100.68 (range $100.37 to $101.23).
- F8Open market sales reported on this line occurred at a weighted average price of $102.37 (range $101.67 to $102.61).
- F9Open market sales reported on this line occurred at a weighted average price of $103.00 (range $103.00 to $103.01).